Type 2 Diabetes Mellitus Clinical Trial
Official title:
Evaluation of the Effect of Moringa Oleifera Tea on Metformin Steady State Plasma Level in Type 2 Diabetes Mellitus Patients - a Pre and Post Non-randomised Trial
Type 2 diabetes mellitus (T2DM) patients from our previous survey tend to co-administer
various herbs with their oral hypoglycemic agents (OHA). Some of these herbs are known to
possess antidiabetic activities. One of such is Moringa oleifera leaves.
The present study evaluated the effects of seven days, twice-daily administration of hot
water infusion of dried Moringa oleifera leaves on the steady state plasma concentrations of
Metformin, one of the most widely used OHAs using T2DM patients who have been on Metformin
for a period of not less than three months. The included patients had also been on Moringa
supplementation but had terminated the use of Moringa at least a month to the start of the
study.
Patients who had other comorbidities such as heart diseases, renal or hepatic impairments
were excluded from the study. The patients were recruited from Endocriniology clinic of the
Obafemi Awolowo University Teaching Hospitals complex, a tertiary hospital from southwest
Nigeria.
Each patient served as his/her control.
Background Plant parts of Moringa oleifera Lam. (Moringaceae) is known to lower blood
glucose level and as a result, type 2 diabetes mellitus patients (T2DM) sometimes use it as
herbal supplements. This study therefore sought to evaluate the effects of coadministration
of Moringa oleifera tea on steady state concentration of metformin in ambulatory T2DM
patients attending a tertiary health facility in Nigeria.
Method This study used a non-randomized pre-test and post-test design to evaluate the
effects of coadministration of Moringa tea and metformin on selected parameters in T2DM
patients. Consented patients, aged 49 -77 years were stabilised on the same brand of
metformin for seven days. On day 8 after an overnight fast, baseline fasting blood sugar
(FBG) and 2-hour post prandial blood sugar (2-hPPBG) were determined using a glucometer.
Blood samples were also collected at the appropriate times for evaluation of serum
creatinine, trough and peak metformin plasma concentrations.
Thereafter, patients were given fourteen sachets of pre-packed 400 g dried Moringa oleifera
leaves for preparation of Moringa tea for seven days (twice daily) while on their normal
doses of metformin. On day 15 after an overnight fast, a repeat of FBG and 2-hPPBG was done
using a glucometer. At the appropriate times, blood samples were also collected for
determination of serum creatinine, trough and peak metformin plasma concentrations.
Serum was obtained from aliquots of the blood samples to determine serum creatinine for
calculation of estimated glomerular filtration rate, eGFR. Plasma was obtained from the
blood samples and were analysed using modified previously-validated HPLC method.
The values of FBG, 2-hPPBG, trough and peak metformin plasma concentrations obtained were
compared with the baseline values using Paired sample t-test at P<0.05 considered
significant in order to evaluate the effect of Moringa tea on the parameters.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |